NEW YORK, June 5, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please
scroll to bottom.
Today, Wall Street Reports announced new research reports
highlighting Health Management Associates Inc. (NYSE: HMA), Boston
Scientific Corporation (NYSE: BSX), Endo Health Solutions Inc.
(NASDAQ: ENDP), Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), and
Cardiovascular Systems Inc. (NASDAQ: CSII). Today's readers may
access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.
Health Management Associates Inc.
Research Report
On May 28, 2013, Health Management
Associates Inc.'s (Health Management Associates) Board of Directors
announced that Gary D. Newsome will
retire as President, Chief Executive Officer and Member of the
Board of Directors, effective July 31,
2013. According to the Company, Mr. Newsome has been called
by the First Presidency of the Church of Jesus Christ of Latter-day Saints to serve as
the President of its Uruguay-Montevideo Mission in South America. The Company affirmed that Mr.
Newsome will continue to lead the Company until his retirement.
Directors Kent P. Dauten,
Donald E. Kiernan, Robert A. Knox, and William J. Schoen will lead the search for a new
Chief Executive Officer. The Full Research Report on Health
Management Associates Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.wsreports.com/r/full_research_report/96e5_HMA]
--
Boston Scientific Corporation Research
Report
On May 27, 2013, Boston Scientific
Corporation (Boston Scientific) announced that it has received CE
Mark approval for use of the GUIDE DBS System, the world's first
deep brain stimulation (DBS) visualization system. GUIDE DBS
creates 3D visualization information that simulates stimulation
output, which may reduce programming time and enable more precise
therapies. Combined with the Vercise DBS System, the GUIDE DBS can
provide the most advanced deep brain stimulation technology to
neurologists, neurosurgeons, and their patients. Both, the GUIDE
DBS and the Vercise DBS, are CE Marked for the treatment of
Parkinson's disease. The Vercise DBS System was approved for sale
in Europe in 2012. The Full
Research Report on Boston Scientific Corporation - including full
detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/5649_BSX]
--
Endo Health Solutions Inc. Research
Report
On May 30, 2013, Endo
Pharmaceuticals, Inc. (Endo Pharmaceuticals), a subsidiary of Endo
Health Solutions, Inc. (Endo Health Solutions) announced that the
U.S. Food and Drug Administration (FDA) issued a complete response
letter regarding the New Drug Application (NDA) for Endo's
long-acting testosterone undecanoate injection, AVEED, for men
diagnosed with hypogonadism. According to the Company, the FDA
outlined the necessary steps to support the approval of the NDA and
requested that the Risk Evaluation and Mitigation Strategy (REMS)
include a Medication Guide as well as Elements to Assure Safe Use
(ETASU) to mitigate risks and severe complications related to
post-injection reactions. However, the complete response letter did
not include requests for the Company to perform additional clinical
studies. Endo Pharmaceuticals plans to submit a complete response
by the end of Q3 2013. The Full Research Report on Endo Health
Solutions Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0e90_ENDP]
--
Achillion Pharmaceuticals, Inc.
Research Report
On May 30, 2013, Achillion
Pharmaceuticals, Inc. (Achillion Pharmaceuticals) announced the
nomination of the preclinical compound, ACH-3422, a novel small
molecule nucleotide prodrug of a uridine analog designed to inhibit
HCV NS5B polymerase. This compound will be used as a development
candidate for the treatment of chronic hepatitis C (HCV) viral
infection. Milind Deshpande, Ph.D.,
Achillion Pharmaceuticals' President and Chief Executive Officer,
said, "The addition of ACH-3422 gives Achillion a portfolio of
assets that also includes a 2nd generation protease inhibitor,
sovaprevir, and a 2nd generation NS5A inhibitor, ACH-3102, which
together provide Achillion the opportunity to potentially optimize
treatment outcomes and duration of therapy across all HCV
patients." The Company plans to complete regulatory submissions in
Q1 2014, with first in-human studies anticipated in the first half
of 2014, followed by combination development in the second half of
2014. The Full Research Report on Achillion Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/0fa0_ACHN]
--
Cardiovascular Systems Inc. Research
Report
On May 30, 2013, Cardiovascular
Systems, Inc. (Cardiovascular Systems) announced that the first
patient has been enrolled in its post-market study, LIBERTY 360.
The study evaluates the acute and long-term clinical and economic
outcomes of CSI's orbital atherectomy system in treating peripheral
arterial disease (PAD). It is also the first study of its kind to
compare orbital atherectomy to all other PAD treatment options in a
difficult-to-treat population. David L.
Martin, CSI President and Chief Executive Officer, said,
"Past studies have proven that treating PAD patients with our
orbital atherectomy system is safe and effective. The LIBERTY 360
study is a massive undertaking looking at a large number of the
most difficult-to-treat patients. CSI is an industry leader in
clinical data support for our physician customers, and we're
dedicated to providing them with the information they need to make
sound treatment decisions for their patients. LIBERTY 360 is the
latest example of our commitment to this and we're excited about
the data and insight it will provide." The Full Research Report on
Cardiovascular Systems Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free
of charge at:
[http://www.wsreports.com/r/full_research_report/1fb2_CSII]
----
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by a CFA. However, we are only
human and are prone to make mistakes. If you notice any errors or
omissions, please notify us below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquires, please contact us
at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research@EquityNewsNetwork.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Equity News Network. An outsourced research services provider has,
through Chartered Financial Analysts, only reviewed the information
provided by Equity News Network in this article or report according
to the Procedures outlined by Equity News Network. Equity News
Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as
to the accuracy or completeness or fitness for a purpose
(investment or otherwise), of the information provided in this
document. This information is not to be construed as personal
financial advice. Readers are encouraged to consult their personal
financial advisor before making any decisions to buy, sell or hold
any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may
be occasioned at the time of printing of this document or any
error, mistake or shortcoming. No liability is accepted by Equity
News Network whatsoever for any direct, indirect or consequential
loss arising from the use of this document. Equity News Network
expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Equity News Network
does not (1) guarantee the accuracy, timeliness, completeness or
correct sequencing of the information, or (2) warrant any results
from use of the information. The included information is subject to
change without notice.
SOURCE Wall Street Reports